<DOC>
	<DOCNO>NCT03021330</DOCNO>
	<brief_summary>In open-label , randomize , prospective clinical trial , newly-diagnosed AML patient randomize 2 group . In experimental arm , patient receive DA induction regimen intermediate dose cytarabine . In control arm , patient receive DA regimen standard dose cytarabine.The efficacy induction therapy contain intermediate dose cytarabine evaluate adverse event associate treatment recorded.The primary end point overall survival .</brief_summary>
	<brief_title>Efficacy Intermediate-Dose Cytarabine Induction Regimen Adult AML</brief_title>
	<detailed_description>In open-label , randomize , prospective clinical trial , newly-diagnosed AML patient randomize 2 group . In experimental arm , patient receive DA induction regimen intermediate dose cytarabine dose 100mg/㎡/d day 1-4 1g/㎡/Q12h day5-7 . In control arm , patient receive DA regimen standard dose cytarabine dose 100mg/㎡/d day 1-7 . Patients receive consolidation therapy contain high-dose cytarabine achieve complete remission . Stem-cell transplantation permit patient intermediate- poor-risk disease . The efficacy induction therapy contain intermediate dose cytarabine evaluate adverse event associate treatment recorded.The primary end point overall survival .</detailed_description>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>1 . Age 14 55 year old ; 2 . Patients meet diagnostic criterion ( WHO 2008 criterion ) AML ( except APL subtypes ) . 3 . ECOG score ≤ 2 ; 4 . Patients eligible laboratory examination include liver , renal heart function . 5 . Adult patient willing participate study sign inform consent immediate family . Patients 18 year old willing participate legal guardian sign inform consent . 1 . Patients receive induction therapy . 2 . Secondary leukemia . 3 . Patients tumor active stage receive radiotherapy chemotherapy last 6 month due tumor . 4 . Patients blood disease ( example , haemophiliac ) excluded.However , patient abnormal blood count , undiagnosed MDS MPD patient include . 5 . Acute panmyelosis myelofibrosis myeloid sarcoma patient ; 6 . With BCRABL fusion gene ; 7 . Pregnant lactating woman ; 8 . AML ineligible renal liver function ; 9 . AML active cardiovascular disease ; 10 . Severe infection disease include uncured tuberculosis pulmonary aspergillosis ; 11 . AIDS ; 12 . Patients central nervous system involvement diagnose AML . 13 . Patients epilepsy dementia mental disease could n't understand follow research . 14 . Drugs , medical , mental social situation may distract patient follow research evaluate result . 15 . Patients factor consider unsuitable participate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>